CRDL vs. ARCT, RVNC, ABVX, HUMA, AURA, RAPP, RNAC, TSHA, ATXS, and HRTX
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Arcturus Therapeutics (ARCT), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Arcturus Therapeutics (NASDAQ:ARCT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Arcturus Therapeutics presently has a consensus target price of $59.20, suggesting a potential upside of 363.59%. Cardiol Therapeutics has a consensus target price of $8.40, suggesting a potential upside of 692.45%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Arcturus Therapeutics.
Cardiol Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 4 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.32 beat Arcturus Therapeutics' score of -0.19 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
Arcturus Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Cardiol Therapeutics' return on equity.
Arcturus Therapeutics received 419 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 66.27% of users gave Arcturus Therapeutics an outperform vote while only 65.85% of users gave Cardiol Therapeutics an outperform vote.
Summary
Arcturus Therapeutics beats Cardiol Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRDL) was last updated on 3/26/2025 by MarketBeat.com Staff
